Xembify® (immune globulin subcutaneous, human - klhw) – New drug approval
July 4, 2019 - Grifols announced the FDA approval of Xembify (immune globulin subcutaneous, human – klhw), for the treatment of primary humoral immunodeficiency (PI) in patients 2 years of age and older.
Download PDF
